Shreyas Joshi, MD, highlights initial promise from pivotal trial of EG-70
January 5th 2025"We're very much looking forward to the new data that'll be presented, hopefully, within the next year, to see where this falls in the grand scheme of the all the new drugs coming into play here," says Shreyas S. Joshi, MD, MPH.
Sarah Psutka, MD, on phase 3 trial of padeliporfin VTP therapy in UTUC
Published: January 2nd 2025 | Updated: January 2nd 2025“This is another therapeutic that adds to UroGen [profile] as a potential treatment that could be used to preserve kidneys while treating low grade upper tract urothelial carcinoma going forward,” says Sarah P. Psutka, MD, MSc.
Shreyas Joshi, MD, highlights trial of EG-70 in NMIBC
December 24th 2024"We're excited about the science behind it, but we're also excited for our patients that if they can have access to this, maybe we can delay or completely avoid radical cystectomy or further aggressive treatments," says Shreyas S. Joshi, MD, MPH.
Raveen Syan, MD, FPMRS, previews the 2025 Urology on the Beach conference
December 19th 2024"What's unique about our conference is the focus is not on just showcasing what our institute has to offer; the real focus is on networking and collaborating with the top institutes in the nation," says Raveen Syan, MD, FPMRS.
Eric Jonasch, MD, on phase 1/2 trial of 177Lu-girentuximab combination in ccRCC
December 18th 2024“We really want to understand whether by using this beta emitter, together with the combination of cabazantinib and the nivolumab, we're getting better outcomes than we would expect with the doublet alone,” says Eric Jonasch, MD.
Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
December 18th 2024“What we've been working on is a giant 30,000 patient database study using the National Cancer Database to see exactly what the rates are of upstaging and downstaging for these larger kidney tumors,” says Taylor Goodstein, MD.